News

Destiny Pharma – Landmark XF-73 Phase 2 data published in journal

Announces publication of XF-73 nasal gel Phase 2 data in leading…

Sequana Medical announces additional patents for DSR® in China and the United States

Ghent, Belgium – 22 March 2023 – Sequana Medical NV (Euronext…

iOnctura Announces Publication Of Pioneering Research Describing The Unique Biological Features Of Roginolisib

Preclinical Data On Roginolisib, An Oral First-In-Class Non-ATP…

Leucid Bio and Great Ormond Street Hospital enter commercial agreement at new gene therapy manufacturing centre

Agreement to manufacture Leucid Lead asset, LEU011 for the…

Five companies receive additional financial support through BioInnovation Institute’s Venture House program

BioInnovation Institute (BII), an international non-profit foundation…

Aldena Therapeutics Accelerates its Novel and Disruptive Approach to Immuno-Dermatology

Founded by Medicxi with Georgia Tech and UMass scientists,…

DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine

Turku, Finland – March 15, 2023 – DelSiTech Ltd, a Finnish…

Synaffix Announces Expansion of ADC Collaboration with MacroGenics

MacroGenics adds up to four ADC programs MacroGenics may…

Positive phase 2 data from Atrial Fibrillation clinical trial – primary endpoint met

First-in-class SK channel inhibition proof of mechanism achieved First…

Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases

Financing co-led by Sunstone Life Science Ventures and…

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…

BioInnovation Institute welcomes innovative mycoprotein meat project into Bio Studio program

BioInnovation Institute (BII), an international non-profit foundation…

Poolbeg Pharma plc: POLB 001 patent portfolio strengthened through granting of US patent

Key highlights ·      Patent granted for use of certain…

Verona Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Transformational results in Phase 3 ENHANCE program for COPD NDA…

Poolbeg Pharma: Positive Results from POLB 001 LPS Human Challenge Trial

Strong potential for POLB 001 to be a blockbuster treatment for…

Ten new companies enter BioInnovation Institute’s Venture Lab program

BioInnovation Institute (BII), an international non-profit foundation…

We’d love to hear from you

For more information about Optimum Strategic Communications, please get in touch.

Get in touch

© Optimum Strategic Communications.